Ionis Pharmaceuticals Inc Total Liabilities
Ionis Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has total liabilities worth $2.56 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Ionis Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ionis Pharmaceuticals Inc (1990–2025)
Total liabilities of Ionis Pharmaceuticals Inc from 1990 to 2025. This chart illustrates how Ionis Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore IONS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Ionis Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Noble Corporation plc
NYSE:NE
|
USA | $2.89 Billion |
|
Air Lease Corporation
NYSE:AL
|
USA | $24.41 Billion |
|
STORA ENSO R ADR 1
F:ENUS
|
Germany | €8.41 Billion |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
USA | $4.70 Billion |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
India | Rs149.67 Billion |
|
First Industrial Realty Trust Inc
NYSE:FR
|
USA | $2.91 Billion |
|
Hainan Airlines Co Ltd A
SHG:600221
|
China | CN¥143.12 Billion |
Liability Composition Analysis (1990–2025)
This chart breaks down Ionis Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ionis Pharmaceuticals Inc balance sheet assets.
Liquidity & Leverage Metrics
Ionis Pharmaceuticals Inc Total Liabilities Ratios Explained
Ionis Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ionis Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ionis Pharmaceuticals Inc (1990–2025)
The table below shows the annual total liabilities of Ionis Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.03 Billion | +25.65% |
| 2024-12-31 | $2.42 Billion | -7.22% |
| 2023-12-31 | $2.60 Billion | +32.76% |
| 2022-12-31 | $1.96 Billion | +6.58% |
| 2021-12-31 | $1.84 Billion | +18.94% |
| 2020-12-31 | $1.55 Billion | -0.06% |
| 2019-12-31 | $1.55 Billion | +4.55% |
| 2018-12-31 | $1.48 Billion | +63.91% |
| 2017-12-31 | $903.30 Million | +11.12% |
| 2016-12-31 | $812.90 Million | +7.62% |
| 2015-12-31 | $755.32 Million | +8.21% |
| 2014-12-31 | $698.03 Million | +48.91% |
| 2013-12-31 | $468.77 Million | +29.17% |
| 2012-12-31 | $362.92 Million | +15.78% |
| 2011-12-31 | $313.46 Million | +2.46% |
| 2010-12-31 | $305.94 Million | -13.85% |
| 2009-12-31 | $355.12 Million | -24.43% |
| 2008-12-31 | $469.90 Million | +89.01% |
| 2007-12-31 | $248.62 Million | +57.35% |
| 2006-12-31 | $158.00 Million | -3.48% |
| 2005-12-31 | $163.71 Million | -41.65% |
| 2004-12-31 | $280.56 Million | +4.78% |
| 2003-12-31 | $267.76 Million | -5.45% |
| 2002-12-31 | $283.21 Million | +46.01% |
| 2001-12-31 | $193.96 Million | +65.94% |
| 2000-12-31 | $116.89 Million | +14.25% |
| 1999-12-31 | $102.31 Million | +2.00% |
| 1998-12-31 | $100.30 Million | +20.84% |
| 1997-12-31 | $83.00 Million | +93.47% |
| 1996-12-31 | $42.90 Million | +81.01% |
| 1995-12-31 | $23.70 Million | +15.05% |
| 1994-12-31 | $20.60 Million | +1.48% |
| 1993-12-31 | $20.30 Million | +29.30% |
| 1992-12-31 | $15.70 Million | +8.28% |
| 1991-12-31 | $14.50 Million | +457.69% |
| 1990-12-31 | $2.60 Million | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more